Wacker Biotech signed an agreement to acquire a production site for biologics from BioNet Ventures. The deal includes the acquisition of the assets of Scil Proteins Production. Wacker will continue to work with Scil’s existing customer partnerships and plans to retain the Scil staff. The transaction is expected to close early next year.
Founded in 2005, Scil has about 80 employees and operates a fermenter in Halle, Germany, with a capacity of up to 1,500 liters. The protein-refolding expertise held by Scil Proteins Production complements Wacker’s know-how in its role as a full-service provider for the microbial manufacture of biologics, according to Gerhard Schmid, president of the Wacker Biosolutions business division.
“We see the acquisition as a crucial step towards extending our service to customers to cover the market-supply phase following approval of customer drugs more adequately,” noted Schmid. “Our partners’ various pharmaceutical projects, which we have proactively supported during preclinical and clinical development, are about to be launched on the market. Expanding our production capacities in this way comes at an ideal time for both ourselves and our customers. Additionally, Scil’s refolding expertise complements our own technology platforms and extends the range of services that we offer as a leading contract manufacturer of biopharmaceutical proteins with microbial technologies.”